Publications and communications of HANSEN, Isabelle

Guillemin, C., Charonitis, M., Beliy, N., Requier, F., Gilsoul, J., Balteau, E., DELRUE, G., LOMMERS, E., HANSEN, I., MAQUET, P., Phillips, C., & Collette, F. (June 2022). Exploring the specificity of fatigue-related brain activity in early Multiple Sclerosis. Poster session presented at OHBM 2022 Annual Meeting, Glasgow, United Kingdom.

Dauby, S., DIVE, D., LUTTERI, L., ANDRIS, C., HANSEN, I., MAQUET, P., & LOMMERS, E. (2021). Comparative study of AQP4‑NMOSD, MOGAD and seronegative NMOSD: a single‑center Belgian cohort. Acta Neurologica Belgica. doi:10.1007/s13760-021-01712-3

Timmermans, G., DEPIERREUX, F., WANG, F.-C., HANSEN, I., & MAQUET, P. (16 August 2019). Cosmetic injection of botulinum toxin unmasking subclinical myasthenia gravis : a case report and literature review. Case Reports in Neurology, 11, 244-251. doi:10.1159/000502350

Daniel, S., LOMMERS, E., HANSEN, I., DIVE, D., GEENEN, V., Beckers, A., & VALDES SOCIN, H. G. (2019). Thyroid dysfunction after Alemtuzumab treatment for multiple sclerosis : diagnostic and therapeutic modalities. In Endocrine Abstracts - ECE 2019.

Daniel, S., HANSEN, I., Dive, D., Geenen, V., Beckers, A., & VALDES SOCIN, H. G. (December 2018). Thyroid dysfunction after Alemtuzumab treatment for multiple sclerosis : a report of four cases. Acta Clinica Belgica, 73 (2).

LOMMERS, E., DEPIERREUX, F., HANSEN, I., DIVE, D., & MAQUET, P. (November 2018). NMOSD with anti-MOG antibodies following anti-TNFα therapy: A case report. Multiple Sclerosis and Related Disorders, 26, 37-39. doi:10.1016/j.msard.2018.08.029

LOMMERS, E., DELRUE, G., REUTER, G., CALAY, P., DELVAUX, V., HANSEN, I., DIVE, D., MAQUET, P., & Phillips, C. (October 2015). Improved probabilistic segmentation of white matter lesions in multiple sclerosis. Poster session presented at 31st congress of the European Committee for Treatment and Research in Multiple Sclerosis.

HANSEN, I., MELON, P., CREEMERS, E., & Moonen, G. (March 2012). Structured differential diagnosis of a transient impairment of consciousness. Revue Médicale de Liège, 67 (3).

Belachew, S., Phan-Ba, R., Bartholome, E., Delvaux, V., Hansen, I., Calay, P., El Hafsi, K., Moonen, G., Tshibanda, L., & Vokaer, M. (February 2010). Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. European Journal of Neurology, 18 (2), 240-245. doi:10.1111/j.1468-1331.2010.03112.x

Zeevaert, B., Hansen, I., Crielaard, J.-M., & Wang, F.-C. (2002). Syndrome du canal lent associe a une translocation autosomique 2q31-9p27. Revue Neurologique, 158 (5 Pt 1), 605-8.

Hansen, I., Petrossians, P., Thiry, A., Flandroy, P., Gaillard, R. C., Kovacs, K., Claes, F., Stevenaert, A., Piguet, P., & Beckers, A. (October 2001). Extensive inflammatory pseudotumor of the pituitary. Journal of Clinical Endocrinology and Metabolism, 86 (10), 4603-4610. doi:10.1210/jc.86.10.4603